Novel partial 5HT3 agonist pumosetrag reduces acid reflux events in uninvestigated GERD patients after a standard refluxogenic meal: a randomized, double-blind, placebo-controlled pharmacodynamic study.

MLA

Choung, R. S., et al. “Novel Partial 5HT3 Agonist Pumosetrag Reduces Acid Reflux Events in Uninvestigated GERD Patients after a Standard Refluxogenic Meal: A Randomized, Double-Blind, Placebo-Controlled Pharmacodynamic Study.” Neurogastroenterology and Motility, vol. 26, no. 1, Jan. 2014, pp. 13–20. EBSCOhost, https://doi.org/10.1111/nmo.12214.

APA

Choung, R. S., Locke, G. R., 3rd, Francis, D. D., Katzka, D., Winkle, P. J., Orr, W. C., Crowell, M. D., Devault, K., Harmsen, W. S., Zinsmeister, A. R., & Talley, N. J. (2014). Novel partial 5HT3 agonist pumosetrag reduces acid reflux events in uninvestigated GERD patients after a standard refluxogenic meal: a randomized, double-blind, placebo-controlled pharmacodynamic study. Neurogastroenterology and Motility, 26(1), 13–20. https://doi.org/10.1111/nmo.12214

Chicago

Choung, R S, G R Locke 3rd, D D Francis, D Katzka, P J Winkle, W C Orr, M D Crowell, et al. 2014. “Novel Partial 5HT3 Agonist Pumosetrag Reduces Acid Reflux Events in Uninvestigated GERD Patients after a Standard Refluxogenic Meal: A Randomized, Double-Blind, Placebo-Controlled Pharmacodynamic Study.” Neurogastroenterology and Motility 26 (1): 13–20. doi:10.1111/nmo.12214.